These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 27355218)
1. Matrix metalloproteinase 9 and prostate cancer risk: a meta-analysis of 1059 participants. Ma F; Wang Z; Abdularab A; Dai L; Niu Y; Jiang N Minerva Urol Nefrol; 2017 Aug; 69(4):324-329. PubMed ID: 27355218 [TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464 [TBL] [Abstract][Full Text] [Related]
3. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679 [TBL] [Abstract][Full Text] [Related]
4. Association between MMP-2 expression and prostate cancer: A meta-analysis. Xie T; Dong B; Yan Y; Hu G; Xu Y Biomed Rep; 2016 Feb; 4(2):241-245. PubMed ID: 26893846 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis. Ren F; Tang R; Zhang X; Madushi WM; Luo D; Dang Y; Li Z; Wei K; Chen G PLoS One; 2015; 10(8):e0135544. PubMed ID: 26270045 [TBL] [Abstract][Full Text] [Related]
6. Clinicohistopathological implications of MMP/VEGF expression in retinoblastoma: a combined meta-analysis and bioinformatics analysis. Zhu J; Zhang X; Ai L; Yuan R; Ye J J Transl Med; 2019 Jul; 17(1):226. PubMed ID: 31311559 [TBL] [Abstract][Full Text] [Related]
7. Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Hu C; Wang J; Xu Y; Li X; Chen H; Bunjhoo H; Xiong W; Xu Y; Zhao J Gene; 2013 Mar; 517(1):65-71. PubMed ID: 23313298 [TBL] [Abstract][Full Text] [Related]
8. Association between MMP-9 -1562 C/T polymorphism and susceptibility to digestive cancers: A meta-analysis. Hu C; Weng F; Li L; Dai W; Yan J; Peng L; Zhou R Gene; 2018 Oct; 673():88-94. PubMed ID: 29890308 [TBL] [Abstract][Full Text] [Related]
9. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Cardillo MR; Di Silverio F; Gentile V Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495 [TBL] [Abstract][Full Text] [Related]
10. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Castellano G; Malaponte G; Mazzarino MC; Figini M; Marchese F; Gangemi P; Travali S; Stivala F; Canevari S; Libra M Clin Cancer Res; 2008 Nov; 14(22):7470-80. PubMed ID: 19010864 [TBL] [Abstract][Full Text] [Related]
11. Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: a meta-analysis based on 3906 subjects. Zhang K; Chen X; Zhou J; Yang C; Zhang M; Chao M; Zhang L; Liang C Oncotarget; 2017 Jul; 8(27):45020-45029. PubMed ID: 28445160 [TBL] [Abstract][Full Text] [Related]
12. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494 [TBL] [Abstract][Full Text] [Related]
13. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness? Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155 [TBL] [Abstract][Full Text] [Related]
14. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort. Srivastava P; Kapoor R; Mittal RD Gene; 2013 Nov; 530(2):273-7. PubMed ID: 23872201 [TBL] [Abstract][Full Text] [Related]
15. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. Liu B; Gu X; Huang T; Luan Y; Ding X Oncol Rep; 2017 Jan; 37(1):201-208. PubMed ID: 28004109 [TBL] [Abstract][Full Text] [Related]
16. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Xiao LJ; Lin P; Lin F; Liu X; Qin W; Zou HF; Guo L; Liu W; Wang SJ; Yu XG Int J Oncol; 2012 May; 40(5):1714-24. PubMed ID: 22200661 [TBL] [Abstract][Full Text] [Related]
17. Differential expression of Low density lipoprotein Receptor-related Protein 1 (LRP-1) and matrix metalloproteinase-9 (MMP-9) in prostate gland: From normal to malignant lesions. Gilardoni MB; Remedi MM; Oviedo M; Dellavedova T; Sarría JP; Racca L; Dominguez M; Pellizas CG; Donadio AC Pathol Res Pract; 2017 Jan; 213(1):66-71. PubMed ID: 27931798 [TBL] [Abstract][Full Text] [Related]
18. Association between matrix metalloproteinase family gene polymorphisms and risk of ischemic stroke: A systematic review and meta-analysis of 29 studies. Misra S; Talwar P; Kumar A; Kumar P; Sagar R; Vibha D; Pandit AK; Gulati A; Kushwaha S; Prasad K Gene; 2018 Sep; 672():180-194. PubMed ID: 29906531 [TBL] [Abstract][Full Text] [Related]
19. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Mehta PB; Jenkins BL; McCarthy L; Thilak L; Robson CN; Neal DE; Leung HY Oncogene; 2003 Mar; 22(9):1381-9. PubMed ID: 12618764 [TBL] [Abstract][Full Text] [Related]
20. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Upadhyay J; Shekarriz B; Nemeth JA; Dong Z; Cummings GD; Fridman R; Sakr W; Grignon DJ; Cher ML Clin Cancer Res; 1999 Dec; 5(12):4105-10. PubMed ID: 10632347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]